No. The opioid epidemic is not over, but it is changing in ways that offer genuine hope for the first time in years. Drug overdose deaths in the United States dropped to an estimated 80,391 in 2024, a 26.9% decline from the 110,037 deaths recorded in 2023. That’s the largest single-year decrease on record, and it brings the death toll below where it stood in 2020. Still, more than 80,000 deaths per year is a staggering number, and the forces driving the crisis are evolving rather than disappearing.
Why Deaths Are Falling
Several factors are converging to push the numbers down. Community distribution of naloxone, the overdose-reversal medication now available over the counter, has proven remarkably effective even as the drug supply has grown more dangerous. A systematic review in BMC Public Health found that survival rates after naloxone administration have held steady despite the shift to fentanyl. In San Francisco, when fentanyl first entered the local supply, health officials scaled up naloxone distribution aggressively. New enrollments in the program jumped 55%, refills increased 89%, and reported overdose reversals rose 113%, all while the city avoided the spike in deaths seen elsewhere.
Prescription opioids, the original spark of the crisis, continue to decline. The national dispensing rate fell from 46.8 prescriptions per 100 people in 2019 to 35.4 per 100 in 2024. That’s a significant shift from the peak years when doctors were writing enough prescriptions to supply nearly every adult in the country.
The declines have reached every demographic group. Black Americans, who had been experiencing the fastest-rising death rates in recent years, saw the largest drop: a 30.9% decrease, from 48.9 to 33.8 deaths per 100,000 people. The youngest age group tracked, ages 15 to 24, saw deaths fall 37%.
The Drug Supply Is More Dangerous Than Ever
The improvement in death counts can obscure a grim reality about what people are actually encountering on the street. Illicitly manufactured fentanyl still dominates the opioid supply. According to DEA laboratory testing, roughly 5 out of every 10 counterfeit pills seized contain 2 milligrams or more of fentanyl, the threshold generally considered lethal for someone without opioid tolerance. That means a single pill disguised to look like a prescription painkiller or anti-anxiety medication is, in effect, a coin flip.
On top of fentanyl, the supply is being cut with xylazine, a veterinary sedative that has no approved use in humans. Deaths involving both fentanyl and xylazine rose from 99 in 2018 to over 6,000 in 2023, an increase of nearly 6,000%. Xylazine doesn’t respond to naloxone because it isn’t an opioid. It’s associated with severe skin wounds and withdrawal symptoms that complicate treatment. Its spread, concentrated initially in the Northeast, has created a new layer of risk for people who use drugs.
Newer Synthetics Are Entering the Picture
Fentanyl may not remain the primary threat forever. A class of synthetic opioids called nitazenes has been appearing in the drug supply with increasing frequency since 2019. Some nitazenes are up to 500 times more potent than morphine, and certain variants cause deeper, longer-lasting respiratory depression than fentanyl, making overdoses harder to reverse. As of early 2024, forensic labs had identified at least 20 unique nitazene compounds in street drugs. They’ve been found not just in heroin and fentanyl but also in counterfeit pills sold as prescription medications like oxycodone and alprazolam.
The numbers are still small compared to fentanyl deaths. But the trajectory is familiar: the DEA’s forensic database logged more than 4,300 nitazene reports between 2019 and recent data, and Tennessee alone saw four times as many nitazene-involved fatal overdoses in 2021 as in 2020. This pattern of quiet emergence followed by rapid escalation is exactly how fentanyl took hold a decade ago.
The Crisis Has Shifted From Painkillers to Polydrug Use
The opioid epidemic is now in what researchers call a “fourth wave.” The first three waves were driven by prescription opioids, heroin, and then fentanyl. The fourth wave is defined by the collision of opioids with stimulants like methamphetamine and cocaine. Unlike previous stimulant epidemics, which tended to rise and fall on their own cycle, the current surge in stimulant deaths is deeply intertwined with opioid use. Among people who reported using heroin in a national survey, methamphetamine use tripled between 2015 and 2017. Nationally, synthetic opioids like fentanyl are involved in 40% of cocaine-related deaths and 14% of deaths attributed to stimulants like meth.
This polydrug pattern makes the crisis harder to address. Someone using cocaine or meth may not know their supply contains fentanyl. Treatment programs designed around opioid addiction may not fully address stimulant dependence. And the risks compound: combining a depressant that slows breathing with a stimulant that strains the heart creates dangers that neither drug poses alone.
Treatment Still Isn’t Reaching Most People
Medications for opioid use disorder, primarily buprenorphine and methadone, are the most effective tools available for keeping people alive and in recovery. They reduce the risk of fatal overdose, help manage cravings, and allow people to stabilize their lives. But as of the most recent comprehensive data, only about 1 in 5 U.S. adults with opioid use disorder were receiving these medications. Just 36% were getting any form of substance use treatment at all.
That gap matters enormously. The 2024 decline in deaths is encouraging, but it was driven largely by harm reduction efforts like naloxone distribution and public health outreach. Those interventions save lives in the moment. Closing the treatment gap is what would shrink the population at risk in the first place. With an estimated 2.5 million adults living with opioid use disorder, the scale of unmet need remains vast.
What “Over” Would Actually Look Like
To put 80,391 deaths in perspective, that number exceeds annual U.S. deaths from car crashes, gun violence, or HIV at its peak. The year-over-year improvement is real and meaningful, especially for the communities and age groups that saw the sharpest declines. But the drug supply is more unpredictable than at any point in the epidemic’s history, new synthetic compounds are emerging, and the majority of people with addiction still can’t access proven treatment.
The opioid epidemic isn’t over. It’s entering a phase where the tools to fight it are better, the death toll is finally falling, and the threats are shape-shifting in ways that could reverse that progress quickly. The decline from 2023 to 2024 is the strongest evidence yet that intervention works. Whether it holds depends on whether that intervention keeps pace with a drug supply that never stops evolving.